The current study specifically investigated bone cell activity in clinical bone metastases (based on expression levels of a predefined set of osteoblast, osteoclast, and osteocyte marker genes) in relation to tumor cell AR activity [7], in order to gain novel insight into biological heterogeneities of possible importance for patient stratification into bone-targeting therapies. Here, AR is linked to neoplasm.